On April 8, the 2024 Wuzhen Health Conference was successfully held. JumpCan Pharmaceutical's exclusive product, Xiao'er Chiqiao Qingre Granules (Tonpei), stood out among numerous star products and wins "Most Popular Star Product in Pharmacies" award again. This award stems from the renewed recognition and affirmation of retail pharmacies and consumers.
Centered around the theme of "Resilience · Mastering Change", the conference integrated six major summits, including the "2024 West Lake Forum", "3rd China OTC Conference", "3rd High-Quality Development Conference for Traditional Chinese Medicine", "China Pharmaceutical Broad Market Conference" and "Medical League Competition", promoting an ecological, systematic, and platform-driven reform that integrates "medical + pharmaceutical + technology + channels + consumers." Thousands of attendees, including government officials, representatives from industry associations, academicians, experts, scholars, and business representatives, gathered to explore new directions for the health industry and pharmaceutical development within the new ecosystem and landscape of health consumption.
Xiao'er Chiqiao Qingre Granules (Tonpei), a well-known pediatric medication, has recently received several honors, including the "2023-2024 Potential Brand in China's Pharmaceutical Retail Market", "10th Place in the 2023 Top 20 Retail List for Respiratory Medications" and "23rd Place in the 2023 Top 50 Retail Rankings for Traditional Chinese Medicines." These accolades reflect the trust of the retail market and consumers in the Tongpei product brand, as well as the industry's high recognition of JumpCan Pharmaceutical and the brand value of Xiao'er Chiqiao Qingre Granules.
Adhering to its corporate mission of "Using Technology to Defend Health", JumpCan Pharmaceutical is committed to providing patients with diverse innovative treatments. In 2023, the company developed Xiao'er Chiqiao Qingre Syrup (K-tonpei), which offers better taste, an improved formulation, and easier administration. As the first improved traditional Chinese medicine approved for market under the new Provisions for Drug Registration, it better meets the diverse medication needs of pediatric patients and provides new treatment options for children.